Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of building a world of connection for people with hearing and balance disorders.
Guidelines: https://bit.ly/3IzmNvU
Company Details
- Employees
- 9
- Address
- 1325 Boylston Street,
- Phone
- (617) 370-8701
- in****@****ltx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- decibeltx.com
- HQ
- Boston, MA
Decibel Therapeutics Questions
Decibel Therapeutics's helpline number is (617) 370-8701
Decibel Therapeutics's website is decibeltx.com
Decibel Therapeutics's LinkedIn profile is https://www.linkedin.com/company/decibel-therapeutics
Decibel Therapeutics has
9 employees.
View email and phone details for 9
employees at Decibel Therapeutics.
Decibel Therapeutics's industry is
Biotechnology Research
Decibel Therapeutics's top competitors are
Vertex Pharmaceuticals,
Eli Lilly And Company,
Amgen,
Akouos,
Source Bio, Inc,
Garuda Therapeutics,
Regeneron,
Bristol Myers Squibb,
Checkmate Pharmaceuticals,
Beam Therapeutics.
Decibel Therapeutics's support email address is info@decibeltx.com
Decibel Therapeutics's categories are Biotechnology Research
